OTCQB: IGXT | TSX-V: IGX

IntelGenx's Robust Product Pipeline Addresses Significant Market Opportunities


Indication
(Molecule)
Partnering
Status
Formulation
Development
Clinical Filing   Launch  Partner
Pipeline versa lagrge flec Migraine - RIZAPORT®
(Rizatriptan)
Available
ex-US, ES & SK
 gensco
 exeltis logo 
intro logo2
flec Erectile Dysfunction - EXORDIA®
(Tadalafil)
Partnered
aquestive logo 
flec Schizophrenia
(Loxapine)
Available
 
flec Neurodegenerative Brain Diseases
(Montelukast)
Available
 
flec Opioid Dependence
(Buprenorphine / Naloxone)
Partnered
 Endo 2018
flec Undisclosed Partnered
 Endo 2018
flec Undisclosed Partnered
iromed logo 
flec Adult-Use and Medical
(Cannabinoids)
Partnered
 tilray
flec Psilocybin Partnered
Screen Shot 2020 08 21 at 1.00.53 PM
flec Psychedelic undisclosed Partnered
logo atai
Pipeline table2 flecorang Pain - Dronabinol AdVersa ®
(Dronabinol)
Available
ex-US & CAN
 fichalogoinsud
flecorang

Hypertension

Partnered
 1 tetr1

Pipeline Disclaimer

The information included on this site reflects IntelGenx Corp. clinical development pipeline and is not intended for promotional purposes. It includes new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of August 25, 2020. IntelGenx assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.